Single-country submissions are 'a step backward' in efforts to promote clinical trial diversity and multi-regional trials, FDA's top oncology official says. • Source: Alamy
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
